logo

TRAW

Traws Pharma·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

TRAW fundamentals

Traws Pharma (TRAW) released its earnings on Aug 14, 2025: revenue was 2.73M (YoY +4689.47%), beat estimates; EPS was -0.16 (YoY +96.71%), missed estimates.
Revenue / YoY
2.73M
+4689.47%
EPS / YoY
-0.16
+96.71%
Report date
Aug 14, 2025
TRAW Earnings Call Summary for Q2,2025
  • Clinical Trial Progress: Phase II COVID studies expected to report by year-end 2025; bird flu trial deferred but ready for quick启动.
  • Financial Highlights: Reduced expenses (R&D -42.5%, G&A -15% YoY), net loss of $0.9M due to one-time charge.
  • Market Potential: $1.5B for COVID drug in underserved patients; bird flu preparedness with BARDA discussions.
EPS
Revenue

Revenue & Expenses

Key Indicators

Traws Pharma (TRAW) key financial stats and ratios, covering profitability, financial health, and leverage.
Traws Pharma (TRAW)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Traws Pharma (TRAW)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Traws Pharma (TRAW)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Traws Pharma (TRAW) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Traws Pharma (TRAW) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield